Wednesday, May 11, 2016
PureTech Health has launched Vor BioPharma, an immuno-oncology company dedicated to developing a new class of targeted cell therapies. The company, which is advancing a novel approach to chimeric antigen receptor (CAR) T-cell therapy, has licensed its core technology from the lab of Vor scientific co-founder, Siddhartha Mukherjee, M.D., Ph.D., assistant professor of Medicine at Columbia University and Pulitzer Prize-winning author of The Emperor of All Maladies: A Biography of Cancer.
A new collaboration between the Duke Clinical Research Institute (DCRI) and SAS will give more researchers access to the largest and oldest cardiovascular database in the world. The DCRI and analytics leader SAS will provide researchers worldwide with data management and analytics tools to explore 45 years of cardiovascular patient data collected by the Duke University Health System.
Worldwide Clinical Trials has opened a new, larger depot site in St. Petersburg, Russia. The new facility—at 1,300 square meters in size—allows for the storage and distribution of a wide range of clinical trial materials with special requirements and conditions for storage, as well as distribution. The new location is one of several Worldwide Clinical Trials depots located in Russia, Georgia and Ukraine.
Orchard Therapeutics, a clinical-stage biotechnology company with operations in London and the U.S., has officially launched with a £21-million Series A financing led by F-Prime Capital. As part of its launch, the company has announced formal partnerships with University College London (UCL), Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), the University of Manchester, the University of California Los Angeles (UCLA) and Boston Children’s Hospital for the development of transformative gene therapies for serious and life-threatening orphan diseases.
Valeant Pharmaceuticals International has formed a new patient access and pricing committee that will be responsible for the pricing of the company’s drugs. The committee will be chaired initially by Joseph Papa, chairman and chief executive officer of Valeant, and will include a multi-disciplinary team of Valeant employees, including doctors, scientists and other executives.